Lung inflammation pathways

Lung inflammation pathways represent the coordinated biological responses of the respiratory system to harmful stimuli, such as pathogens, pollutants, or allergens. These pathways are initiated by the recognition of damage-associated or pathogen-associated molecular patterns (DAMPs/PAMPs) by pattern recognition receptors on airway epithelial cells and alveolar macrophages [Source: NIH/StatPearls]. Activation leads to the production of pro-inflammatory mediators, including cytokines (e.g., TNF-alpha, IL-1 beta, IL-6) and chemokines, which facilitate the recruitment of inflammatory cells like neutrophils and eosinophils to the lung tissue [Source: PubMed]. Key intracellular signaling nodes, such as the NF-kappaB and JAK/STAT pathways, play central roles in orchestrating these responses. While essential for host defense, chronic or excessive activation of these pathways is a hallmark of respiratory diseases such as asthma, COPD, and ARDS [Source: Nature Reviews Immunology]. Pharmacological intervention typically targets specific components of these pathways, such as leukotriene receptors, cytokine signaling, or broad-spectrum suppression via corticosteroids, to mitigate tissue damage and restore lung function.

Other names

Pulmonary inflammatory signalingRespiratory inflammation cascadesLung immune response pathways

Inhibition of pro-inflammatory cytokine signaling, antagonism of G protein-coupled receptors, modulation of gene transcription, and inhibition of intracellular kinase cascades.